MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma

Hongqing Zhuang1,*, Jing Bai2,*, Joe Y. Chang3, Zhiyong Yuan1, Ping Wang1

1 Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, and Tianjin Lung Cancer Center, Tianjin, China
2 Department of Radiotherapy, Baotou Cancer Hospital, Neimenggu, China
3 Department of Radiation Oncology, Division of Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA

*These authors have contributed equally to this work

Correspondence to: Hongqing Zhuang, email: hongqingzhuang@163.com

Keywords: erlotinib, radiation, drug resistance, everolimus, mTOR

Received: April 19, 2016 Accepted: September 20, 2016 Published: October 04, 2016

ABSTRACT

Objective: To investigate the effects of mTOR inhibition on drug resistance in lung adenocarcinoma after combined radiation and erlotinib therapy.

Results: Combined radiation and erlotinib therapy produced clear radiosensitization effects both in vitro and in vivo; however, tumor cells remained drug resistant. Additionally, combined radiation and erlotinib therapy significantly increased p-AKT and p-P70 levels. After mTOR inhibition, the number of surviving cells significantly decreased compared with that before inhibition, and the in vivo growth curve was significantly reduced.

Methods: The effects of combined radiation and erlotinib therapy on tumor inhibition and drug resistance were evaluated by in vitro survival curves in PC9 lung adenocarcinoma cell line and in vivo growth curves in nude mouse xenograft tumor model respectively. The association between tumor drug resistance and the phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K-AKT-mTOR) pathway was measured by western blot, assessing the changes in protein kinase B (AKT), phosphor-AKT (p-AKT), P70, and p-P70 protein levels. MTOR was inhibited using everolimus, and changes in AKT, p-AKT, P70, and p-P70 levels were observed. Furthermore, changes in in vitro survival curves, and in vivo growth curves before and after mTOR inhibition were evaluated to confirm its effects on drug resistance in lung adenocarcinoma after combined radiation and TKI therapy.

Conclusion: mTOR was associated with drug resistance in lung adenocarcinoma after radiation combined with TKI, and MTOR inhibition reversed drug resistance in lung adenocarcinoma after combined radiation and TKI therapy.

INTRODUCTION

Increasing applications for radiotherapy combined with tyrosine kinase inhibitors (TKIs) are evident in clinical practice [1–5], but drug resistance after this combination therapy is common in patients [5–10]. However, current treatment of this drug resistance mostly involves treatment of simple TKI drug resistance [6–10]; the mechanism of this drug resistance after the combined radiation and TKI therapy remains unknown. This study investigated the expression changes in the phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K-AKT-MTOR) pathway after combined radiation and TKI therapy and this pathway’s inhibition to reverse drug resistance, which could provide potential targets and ideas for resolving clinical drug resistance after combined radiotherapy and TKI.
RESULTS

Tumor inhibition and drug resistance after combined erlotinib and radiation treatment

By measuring surviving fraction in vitro and tumor volumes in vivo, erlotinib and radiation both had inhibitory effects on tumor cells. However, after long-term treatment, colony formation survival curves revealed that the final surviving fraction was 0.019±0.008, even after combination therapy. Additional tumor cells were drug-resistant and formed colonies after combined erlotinib and radiation therapy. For xenograft tumors, the combined action of erlotinib and radiation produced a greater inhibitory effect than that of each individual agent. However, tumor volumes still slowly increased after 6 weeks of treatment (SF, and growth curve results are shown in Figure 1). Thus, these results showed that erlotinib combined with radiation had synergistically inhibited tumor growth; however, some cells remained drug resistant.

Association between drug resistance and PI3K-AKT-mTOR pathway activity

By western blot, changes in total AKT and P70 protein expression between single-agent erlotinib or radiation treatment and combined treatment were not significantly different. However, p-AKT and p-P70 expression significantly increased compared with that in control group; in addition, p-AKT and p-P70 expression in the combined erlotinib and radiation treatment group was higher than that in the single-agent treatment groups (western blot and densitometry measurements are shown in Figure 2). Thus, these results showed that erlotinib and radiation both increased PI3K-AKT-mTOR pathway activity. This pathway activity also increased significantly after combined erlotinib and radiation therapy.

Changes in PI3K-AKT-mTOR pathway activity after mTOR inhibition with everolimus

The drug resistance induced by radiation combined with erlotinib was inhibited by everolimus in tumor cells and xenograft tumors in nude mice. Western blot showed that protein expression of total AKT and P70 was not significantly altered; however, p-AKT expression slightly increased, and p-P70 expression, both in vivo and in vitro, significantly decreased compared with that in the combined radiation and erlotinib group. These results further confirmed that the PI3K-AKT-mTOR pathway is an important route for the development of drug resistance (Figure 3).

The effect of everolimus on drug resistance in adenocarcinoma after combined radiation and TKI therapy

After p-P70S6K expression was reduced by everolimus, further treatment showed that the number of surviving cells significantly decreased compared with that in the combined erlotinib and radiation group. In addition, everolimus treatment at week 6 (when tumor xenograft began to progress) significantly inhibited tumor growth, and the growth curve turned downward (Figure 4). Thus, these results showed that after drug resistance induced by combined radiation and erlotinib treatment occurred in tumors, everolimus was able to reverse this drug resistance.

Figure 1: Tumor inhibition and drug resistance after combined erlotinib and radiation treatment. A. The survival fractions of radiation alone group, and combined radiation and erlotinib group in vitro. SER=2.18. P value less than 0.05 of comparison of two curves. But the final surviving fraction was 0.019±0.008, even after combination therapy. B. The growth curves of radiation alone group, and combined radiation and erlotinib group in vivo. When the curve of combination treatment compared with the other curves, all the P values were less than 0.05. However, after 6 weeks, the tumor volumes increased again even under combination treatment.
DISCUSSION

The PI3K-AKT-mTOR pathway is an important pathway underlying drug resistance induced by combined radiation and TKI therapy, and inhibiting mTOR can reverse this drug resistance in lung adenocarcinoma.

The cross-talk between the EGFR-KRAS-MAPK-ERK and PI3K-AKT-mTOR pathways, the activation of the PI3K-AKT-mTOR pathway by TKI and radiation produce conditions favorable for using everolimus to reverse drug resistance in tumors after combination therapy. First, the EGFR-KRAS-MAPK-ERK pathway can communicate with PI3K through alternative pathways. With the long-term inhibition of EGFR, PI3K-AKT-mTOR pathway activity can be activated through alternative pathways to maintain cell survival, escape TKI attack, and generate secondary drug resistance [16, 17]. In addition, many studies have shown that radiation can increase the activity of the downstream PI3K-AKT-mTOR pathway members through c-MET, which is an important mechanism underlying drug resistance to TKI [18, 19]. With combined TKI and radiation therapy, the PI3K-AKT-mTOR pathway receives double stimulation, and its activity significantly increases, thus producing resistance to radiation and TKI treatment [20–24]. Therefore, the PI3K-AKT-mTOR pathway becomes the interaction point of their action and an important pathway to regulate drug resistance. As an important drug that inhibits mTOR, everolimus decreases mTOR pathway activity, thus reverses drug resistance in tumors.

TKI drug resistance is a longstanding issue; however, drug resistance after radiation combined with TKI should have some similarities and differences from single-agent TKI drug resistance, but no current studies have addressed this question. This study suggested that the PI3K-AKT-mTOR pathway is an important mechanism underlying drug resistance after radiotherapy combined with TKI. Everolimus could reverse this drug resistance induced by combined radiation and TKI therapy in lung adenocarcinoma, which provides an important potential target to treat drug resistance in patients after combination therapy. Indeed, other pathways besides the PI3K-AKT-mTOR pathway could also contribute to drug resistance in tumor cells after combined TKI and radiation. We are currently performing further studies on other possible underlying mechanisms, such as changes in T790M,

Figure 2: Association between drug resistance and PI3K-AKT-mTOR pathway activity. A. The AKT, p-AKT, P70, p-P70 expression of PC9 cell line in vitro. A1. The Western blot electrophoresis of the different treatment groups. A2. The Gray value histogram of the AKT, p-AKT, P70, p-P70 expression in vitro. B. The AKT, p-AKT, P70, p-P70 expression in vivo. B1. The western blot electrophoresis of the different treatment groups. B2. The Gray value histogram of the AKT, p-AKT, P70, p-P70 expression. P-AKT and p-P70 expression significantly increased compared with that of the control group; in addition, p-AKT and p-P70 expression in the combined erlotinib and radiation treatment group was higher than that in the single-agent treatment groups. These results showed that erlotinib and radiation both increased PI3K-AKT-mTOR pathway activity in vitro and in vivo.
Figure 3: The drug resistance induced by radiation combined with erlotinib was inhibited by everolimus. A. The AKT, p-AKT, P70, p-P70 expression of PC9 cell line in vitro. A1. The Western blot electrophoresis of the different treatment groups. A2. The Gray value histogram of the AKT, p-AKT, P70, p-P70 expression in vitro. B. The AKT, p-AKT, P70, p-P70 expression in vivo. B1. The western blot electrophoresis of the different treatment groups. B2. The Gray value histogram of the AKT, p-AKT, P70, p-P70 expression. Western blot showed that protein expression of total AKT and P70 was not significantly altered; however, p-AKT expression slightly increased, and p-P70 expression, both in vivo and in vitro, significantly decreased in combined radiation, erlotinib and everolimus group compared with those in the combined radiation and erlotinib group.

Figure 4: The effect of everolimus on drug resistance in adenocarcinoma after combined radiation and TKI therapy. A. The survival fraction of different treatment groups in vitro. SER$_{R\,vs\,E\times R}$ = 1.95, SER$_{E\times R\times Ev\,vs\,E\times R}$ = 2.27. The final surviving fraction of 10Gy dose was 0.008±0.003 at E×R×Ev group. P value less than 0.05 of comparison of each groups. B. The growth curve of different treatment groups in vivo. Everolimus treatment at week 6 (when tumor xenograft began to progress) significantly inhibited tumor growth, and the growth curve turned downward.
the effect of radiation on common genes in TKI drug resistance, and the effect of TKI on common genes in radiation resistance.

In summary, radiation is an important mechanism that induces changes in gene expression. Radiotherapy combined with TKI has been extensively applied in clinical practice. Drug resistance in lung adenocarcinoma after combined radiotherapy and TKI should be largely different from that induced by single-agent TKI therapy. This study suggests that the PI3K-AKT-mTOR pathway is an important mechanism underlying drug resistance after combined radiation and TKI therapy and provides ideas and potential targets to reverse this drug resistance. Although additional mechanisms still requiring further study exist, we believe that with continuous in-depth, basic studies and continuous accumulation of clinical practice data, the drug resistance induced by radiotherapy combined with TKI will eventually be resolved.

**MATERIALS AND METHODS**

**Agents, cell line and nude mice**

RPMI-1640 culture medium was obtained from Gibco (USA, Grand Island), and fetal bovine serum was obtained from Sijiqing Biological Engineering Materials Co., Ltd(Hangzhou, China). Monoclonal antibodies targeting AKT, phosphorylated AKT(p-AKT), P70, phosphorylated P70(p-P70) were purchased from Santa Cruz Biotecnology, Inc. (USA, Dallas, Texas). The CO\(_2\) incubator used for cell culture was purchased from Heraeus (Germany, Frankfurt), and the high-speed refrigerated centrifuge was also obtained from Heraeus. The flow cytometer was from Beckman Coulter, Inc. (USA, California). The PC9 lung adenocarcinoma cell line with high levels of epidermal growth factor receptor (EGFR) and phospho-EGFR, as reported previously [11, 12] was used in this study. Cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, 100 IU/ml penicillin, and 100 IU/ml streptomycin in a 37°C incubator with an atmosphere of 5% CO\(_2\). Cells in the exponential growth phase were irradiated. BALB/c-\(\nu\) female nude mice of 5-6 weeks were used in the SPF condition of the ultra clean laminar flow frame.

**Colony-forming analysis**

Colony-forming rates of the tumor cells were determined using the colony formation assay. The experiments on erlotinib-induced radiosensitization included the following treatment groups: control group, radiation alone group, erlotinib alone group, everolimus alone group, combined erlotinib and radiation group, and combined erlotinib and radiation with everolimus group. Cells in the exponential growth phase were trypsinized, counted, diluted, and seeded onto 35.ml flasks. The number of cells seeded onto the flasks was adjusted according to the radiation dose (500, 1000, 2000, 4000, 6000, 8000, and 10000 cells were seeded in 0, 1, 2, 4, 6, 8, and 10 Gy groups, respectively). The concentrations of erlotinib and everolimus used were 20 nM and 10 nM in vitro, respectively. A radiation dose of 2 Gy/min was selected, and cells were exposed to 0, 1, 2, 4, 6, 8, or 10 Gy of radiation after the attachment of cells on the plastic. After 14 days of cell seeding, the culture dishes were collected, and the culture medium was discarded. Cells were fixed and subjected to Giemsa staining. The number of colonies containing more than 50 cells was counted, and the cell survival fraction (SF) was calculated. The single-hit, multi-target model was used to fit the cell survival curves [13]. The experiments were confirmed three times, and each treatment group contained three parallel samples.

**Xenograft analysis**

PC9 cells were digested with exponential growth phase, counted and centrifuged at 1 000r/min for 5 min. Cells were suspended and about \(1 \times 10^6\) cells was injected into the thigh root of the nude mice. The tumors were observed 3 times a week after inoculation. When the tumor grew to about 1 cm of the diameter, the experimental treatment started. The groups were same as the in vitro experiment, and the radiation doses were same to those in vitro. In vivo experiment, both erlotinib and everolimus were used in 2 mg/kg body weight. Animals’ care was in accordance with institution guidelines.

**Western blotting**

The expressions of AKT, p-AKT, P70, and p-P70 in the control group, radiation alone group, erlotinib alone group, everolimus alone group, combined erlotinib and radiation group, and combined erlotinib and radiation with everolimus group were examined using Western blotting. The treatments of erlotinib and the everolimus were the same as those described above. Cells were irradiated at a dose of 6 Gy. The experimental procedures were performed as follows: 14 days after treatment, the cells were trypsinized and collected. In in vivo experiments, the tumors were observed for eight weeks, and then the mice were killed, and the tumors were removed. The total protein was extracted, and the protein concentration was determined by Coomassie brilliant blue staining. The proteins were separated by polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes. The membranes were then probed with primary antibodies, washed, incubated with horseradish peroxidase–conjugated secondary antibodies, and washed again. Finally, protein signals were visualized [14, 15].
Statistical analysis

Origin7.5 software (OriginLab Corporation) was used to fit the cell survival curves. The line charts were drawled with Excel. Data were presented as the mean ± standard deviation and were analyzed using SPSS17.0 software (IBM Corporation). The analysis of student’s t test was used to perform comparisons among multiple groups. P values less than 0.05 were considered statistically significant.

Abbreviations

C: control group; R: radiation group; E+R: combined radiation and erlotinib group; E+R+Ev: combined radiation, erlotinib and everolimus group.

ACKNOWLEDGMENTS

This research was supported by National Natural Science Foundation of China (81301925).

CONFLICTS OF INTEREST

We declared that there were no any financial and personal relationships with other people or organizations that could inappropriately influence the work.

REFERENCES

1. Zhuang H, Zhao X, Zhao L, Chang JY, Wang P. Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancer. Drug Des Devel Ther. 2014. 8:667-75.
2. Chang CC, Chi KH, Kao SJ, Hsu PS, Tsang YW, Chang HJ, Yeh YW, Hsieh YS, Jiang JS. Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience. Lung Cancer. 2011. 73:189-194.
3. Zhuang H, Yuan Z, Wang J, Zhao L, Pang Q, Wang P. The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma. Int J Cancer. 2013. 133:2277-83.
4. Zhuang H, Wang J, Zhao L, Yuan Z, Wang P. Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma. Drug Des Devel Ther. 2013. 7:1179-86.
5. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013. 31:895-902.
6. Zhuang HQ, Zhuang H, Bo Q3, Guo Y, Wang J, Zhao LJ, Yuan ZY, Wang P. Experimental study on the regulation of erlotinib-induced radiosensitization with an anti-c-MET monoclonal antibody. Cancer Cell Int. 2014 Nov 30;14:109.
7. Zhuang HQ, Yuan ZY, Wang J, Wang P, Zhao LJ, Zhang BL. Research progress on criteria for discontinuation of EGFR inhibitor therapy. Onco Targets Ther. 2012. 5:263-70.
8. Tan CS, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 2015. 16:e447-59.
9. Wu SG, Liu YN, Tsai MF, Chang YL, Yu CJ, Yang PC, Yang JC, Wen YF, Shih JY. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget. 2016. 7:12404-13. doi: 10.18632/oncotarget.7189.
10. Zheng D, Ye X, Zhang MZ, Sun Y, Wang JY, Ni J, Zhang HP, Zhang L, Luo J, Zhang J, Tang L, Su B, Chen G, et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Rep. 2016. 6:20913.
11. Li XQ, Liu JT, Fan LL, Liu Y, Cheng L, Wang F, Yu HQ, Gao J, Wei W, Wang H, Sun GP. Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy. Oncotarget. 2016. 7:24585-95. doi: 10.18632/oncotarget.8358.
12. La Monica S, Madeddu D, Tiseo M, Vivo V, Galetti M, Cretella D, Bonelli M, Fumarola C, Cavazzoni A, Falco A, Gervasi A, Lagrasta CA, Naldi N, et al. Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation. J Thorac Oncol. 2016. 11:1051-63.
13. Chu PM, Chiou SH, Su TL, Lee YJ, Chen LH, Chen YW, Yen SH, Chen MT, Chen MH, Shih YH, Tu PH, Ma HI: Enhancement of radiosensitivity in human glioblastoma cells by the DNA N-mustard alkylating agent BO-1051 through augmented and sustained DNA damage response. Radiat Oncol. 2011. 19;6:7.
14. Quanz M, Berthault N, Roulin C, Roy M, Herbette A, Agrario C, Alberti C, Josserand V, Coll JL, Sastre-Garau X, Cosset JM, Larue L, Sun JS, et al. Small-molecule drugs mimicking DNA damage: a new strategy for sensitizing tumors to radiotherapy. Clin Cancer Res. 2009. 15:1308–1316.
15. La Monica S, Madeddu D, Tiseo M, Vivo V, Galetti M, Cretella D, Bonelli M, Fumarola C, Cavazzoni A, Falco A, Gervasi A, Lagrasta CA, Naldi N, et al. Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation. J Thorac Oncol. 2016. 11:1051-63.
16. Chu PM, Chiou SH, Su TL, Lee YJ, Chen LH, Chen YW, Yen SH, Chen MT, Chen MH, Shih YH, Tu PH, Ma HI: Enhancement of radiosensitivity in human glioblastoma cells by the DNA N-mustard alkylating agent BO-1051 through augmented and sustained DNA damage response. Radiat Oncol. 2011. 19;6:7.
17. Quanz M, Berthault N, Roulin C, Roy M, Herbette A, Agrario C, Alberti C, Josserand V, Coll JL, Sastre-Garau X, Cosset JM, Larue L, Sun JS, et al. Small-molecule drugs mimicking DNA damage: a new strategy for sensitizing tumors to radiotherapy. Clin Cancer Res. 2009. 15:1308–1316.
18. Hong-Qing Zhuang, Jian Sun, Zhi-Yong Yuan, Chang-Li Wang. Radiosensitizing effects of gefitinib at different administration times in vitro. Cancer Sci. 2009. 100:1520-1525.
19. Kang XH, Xu ZY, Gong YB, Wang LF, Wang QZ, Xu L, Cao F, Liao MJ: Bufalin Reverses HGF-Induced Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer Cells via Blockage of Met/PI3k/Akt Pathway and Induction of Apoptosis. Evid Based Complement Alternat Med. 2013. 2013:243859.
17. Kuger S, Graus D, Brendtke R, Günther N, Katzer A, Lutyj P, Polat B, Chatterjee M, Sukhorukov VL, Flentje M, Djuzenova CS. Radiosensitization of glioblastoma cell lines by the dual PI3K and mTOR inhibitor NVP-BEZ235 depends on drug-irradiation schedule. Transl Oncol. 2013. 6:169–179.

18. De Bacco F, Luraghi P, Medico E, Reato G, Girolami F, Perera T, Gabriele P, Comoglio PM, Boccaccio C. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst. 2011. 103:645–661.

19. Liu X, Yao W, Newton RC, Scherle PA. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs. 2008. 17:997–1011.

20. Maines MD, Biliverdin R. PKC interaction at the cross-talk of MAPK and PI3K signaling pathways. Antioxid Redox Signal. 2007. 9:2187–2195.

21. Aksamitiene E, Kiyatkin A, Kholodenko BN. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc Trans. 2012. 40:139–146.

22. Menges CW, McCance DJ. Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor. Oncogene. 2008. 27:2934–2940.

23. Jung KH, Park BH, Hong SS. Progress in cancer therapy targeting c-Met signaling pathway. Arch Pharm Res. 2012. 35:595–604.

24. Burris HA. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 2013. 71:829–842.